Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FLGT
SELLFulgent Genetics, Inc. · Healthcare · United States · $559M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Fulgent Genetics, Inc. is a technology company providing comprehensive genetic testing and genomic data solutions across inherited diseases, cancer, and infectious diseases. The company's competitive moat is its proprietary, high-throughput next-generation sequencing (NGS) platform and advanced bioinformatics, enabling rapid, cost-effective, and highly accurate diagnostic testing. Fulgent leverages its scalable technology to offer an extensive test menu and cater to a broad clinical and research market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 619.0M | 289.2M | 283.5M | 322.7M | -19.5% | 320.3M | 350.9M | 402.3M | 11.7% |
| EPS | 4.76 | -5.63 | -1.41 | -1.97 | — | -2.40 | -1.57 | -1.53 | — |
| Shares | 29.4M | 29.7M | 30.8M | 31.1M | +5.6% | 28.4M | — | — | — |
| Debt | 38.9M | 15.3M | 8.5M | 7.7M | -41.8% | 10.2M | — | — | — |
| Equity | 1.3B | 1.1B | 1.1B | 1.1B | -4.2% | — | — | — | — |
| Op CF | 253.5M | 27.0M | 21.1M | -101.6M | -71.2% | -90.1M | — | — | — |
| Inv CF | -261.3M | 38.9M | -58.4M | 111.4M | — | — | — | — | — |
| Fin CF | -77.1M | -47.8M | -4.8M | -14.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FLGT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FLGT | Fulgent Genetics, Inc.(you) | $559M | 27 | SELL |
| MYGN | Myriad Genetics, Inc. | $530M | 35 | HOLD |
| CSTL | Castle Biosciences, Inc. | $749M | 19 | STRONG SELL |
| OPK | OPKO Health, Inc. | $921M | 34 | SELL |
| PSNL | Personalis, Inc. | $1.3B | 22 | SELL |
| BDSX | Biodesix, Inc. | $228M | 38 | HOLD |
| FRNM | Freenome, Inc. | $1.2B | 11 | STRONG SELL |
| WGS | GeneDx Holdings Corp. | $1.8B | 14 | STRONG SELL |
| GRAL | GRAIL, Inc. | $2.9B | 21 | SELL |
| XGN | Exagen Inc. | $113M | 17 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%